{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:04:47Z","timestamp":1789686287617,"version":"4.0.1"},"reference-count":137,"publisher":"Informa UK Limited","issue":"17","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,11,22]]},"DOI":"10.1080\/14656566.2025.2601050","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:28:08Z","timestamp":1765996088000},"page":"1817-1830","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment"],"prefix":"10.1080","volume":"26","author":[{"given":"Aiman","family":"Arraf","sequence":"first","affiliation":[{"name":"Rambam Medical Center","place":["Haifa, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Kharouf","sequence":"additional","affiliation":[{"name":"Hebrew University of Jerusalem","place":["Jerusalem, Israel"]},{"name":"University of Toronto","place":["Toronto, Canada"]},{"name":"University Health Network","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[{"name":"University of Toronto","place":["Toronto, Canada"]},{"name":"University Health Network","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ-2024-081860"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2384705"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00293-y"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.058"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25513"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207980"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160532"},{"key":"e_1_3_6_13_1","volume-title":"Genetic determinants of psoriatic arthritis","author":"Chandran V","year":"2014","unstructured":"Chandran V. Genetic determinants of psoriatic arthritis. University of Toronto; 2014."},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004636"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-1148"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07649-9"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2562311"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/0115733971339350240830104424"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056457"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152639"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0653"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25112"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02417-x"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03518-7"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0314.POD08"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.905741"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152859"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac607"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00654-5"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1024"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02303-0"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02302-9"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00708-8"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.643"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.493"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014"},{"key":"e_1_3_6_40_1","unstructured":"Sun Pharmaceutical Industries Limited. A phase III randomized double-blind single-dose placebo-controlled study to demonstrate the efficacy and safety of Tildrakizumab in subjects with active psoriatic arthritis I (INSPIRE 1) [internet]. Report no.: NCT04314544. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04314544"},{"key":"e_1_3_6_41_1","unstructured":"Sun Pharmaceutical Industries Limited. A phase III randomized double-blind placebo-controlled study to demonstrate the efficacy and safety of tildrakizumab in anti-TNF na\u00efve subjects with active psoriatic arthritis II (INSPIRE 2) [internet]. Report no.: NCT04314531. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04314531"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.388"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.117"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20553"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2701"},{"key":"e_1_3_6_47_1","first-page":"S0003\u20134967(25)0","article-title":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study","author":"Kivitz A","year":"2025","unstructured":"Kivitz A, Baraliakos X, Muensterman ET, et al. Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study. Ann Rheum Dis. 2025;S0003\u20134967(25)01041\u20136.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_6_48_1","unstructured":"Takeda. A multi-center randomized double-blind placebo- and active-controlled phase 3 study to evaluate the efficacy and safety of Zasocitinib (TAK-279) in subjects with active psoriatic arthritis who are na\u00efve to biologic disease-modifying antirheumatic drugs (LATITUDE-PsA-3001) [internet]. Report no.: NCT06671483. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06671483"},{"key":"e_1_3_6_49_1","unstructured":"Takeda. A multi-center randomized double-blind and placebo-controlled phase 3 study to evaluate the efficacy and safety of Zasocitinib (TAK-279) in subjects with active psoriatic arthritis stratified by prior biologic use (LATITUDE-PsA-3002) [internet]. Report No.: NCT06671496. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06671496"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/eeglsa"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42519"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.426"},{"key":"e_1_3_6_54_1","unstructured":"Janssen Research & Development LLC. A phase 3 multicenter randomized double-blind placebo-controlled study evaluating the efficacy and safety of JNJ-77242113 for the treatment of biologic-na\u00efve participants with active psoriatic arthritis [internet]. Report no.: NCT06878404. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06878404"},{"key":"e_1_3_6_55_1","unstructured":"Janssen Research & Development LLC. A phase 3 multicenter randomized double-blind placebo-controlled study evaluating the efficacy and safety of JNJ-77242113 for the treatment of biologic-experienced participants with active psoriatic arthritis [internet]. Report no.: NCT06807424. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06807424"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.35"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.04.014"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2209920"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.019"},{"key":"e_1_3_6_60_1","unstructured":"Acelyrin Inc. Acelyrin announces pipeline reprioritization and provides corporate update [internet]. U.S. Securities and Exchange Commission; 2024 [cited 2025 Sep 27]. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1962918\/000196291824000104\/slrn-8kx8132024xexx991.htm?utm"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02900-y"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00332-6"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065994"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0989-0"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2"},{"key":"e_1_3_6_67_1","unstructured":"Sonelokimab for psoriatic arthritis: 24-week results from the phase II ARGO trial [internet]. PsOPsA Hub; [cited 2025 Sep 22]. Available from: https:\/\/psoriasis-hub.com\/medical-information\/sonelokimab-for-psoriatic-arthritis-24-week-results-from-the-phase-ii-argo-trial"},{"key":"e_1_3_6_68_1","unstructured":"Impact of sonelokimab a novel IL-17A- and IL-17F-inhibiting nanobody in active psoriatic arthritis: key subgroup analyses in the randomized double-blind placebo-controlled phase 2 ARGO trial [internet]. ACR Meeting Abstracts; [cited 2025 Sep 22]. Available from: https:\/\/acrabstracts.org\/abstract\/impact-of-sonelokimab-a-novel-il-17a-and-il-17f-inhibiting-nanobody-in-active-psoriatic-arthritis-key-subgroup-analyses-in-the-randomized-double-blind-placebo-controlled-phase-2-argo-trial\/"},{"key":"e_1_3_6_69_1","unstructured":"Sonelokimab in biologic-experienced patients with active psoriatic arthritis: results from a phase 2 trial (ARGO) and study design of a phase 3 trial (IZAR-2) in patients with inadequate response or intolerance to biologic TNFi including a risankizumab reference arm [internet]. ACR Meeting Abstracts; [cited 2025 Sep 22]. Available from: https:\/\/acrabstracts.org\/abstract\/sonelokimab-in-biologic-experienced-patients-with-active-psoriatic-arthritis-results-from-a-phase-2-trial-argo-and-study-design-of-a-phase-3-trial-izar-2-in-patients-with-inadequate-response-or-i\/"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.118"},{"key":"e_1_3_6_71_1","unstructured":"MoonLake Immunotherapeutics AG. A phase 3 parallel-group randomized double-blind 3-arm placebo-controlled multicenter study to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs [internet]. Report no.: NCT06641076. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06641076"},{"key":"e_1_3_6_72_1","unstructured":"MoonLake Immunotherapeutics AG. A phase 3 parallel-group randomized double-blind 4-arm placebo-controlled multicenter study with risankizumab as active reference arm to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-\u03b1 inhibitors [internet]. Report no.: NCT06641089. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06641089"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.056"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21711"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1194-8"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00368"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201299"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201273"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1810-5"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3145-0"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2592-3"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1446468"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.12.039"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04609.x"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1694"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-025-03898-4"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.05.021"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2232-3"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.03.002"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2024.501809"},{"key":"e_1_3_6_94_1","unstructured":"University Health Network Toronto. Clinical evaluation of psoriatic arthritis treated with liraglutide. The plaque study: psoriatic arthritis treated with liraglutide therapy: a quality of life and efficacy study [internet]. Report no.: NCT02472717. Available from clinicaltrials.gov; 2017 [cited 2025 Sep 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02472717"},{"key":"e_1_3_6_95_1","unstructured":"Eli Lilly and Company. Efficacy and safety of ixekizumab or ixekizumab concomitantly administered with tirzepatide in adult participants with active psoriatic arthritis and obesity or overweight: a phase 3b randomized multicenter open-label study (TOGETHER-PsA) [internet]. Report no.: NCT06588296. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06588296"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00574-w"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.2506241.dtt"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i15.2068"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00427-7"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.09.010"},{"issue":"9","key":"e_1_3_6_104_1","first-page":"406","article-title":"Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature","volume":"17","author":"Gold SL","year":"2021","unstructured":"Gold SL, Steinlauf AF. Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature. Gastroenterol Hepatol (NY). 2021;17(9):406\u2013414.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"e_1_3_6_105_1","unstructured":"Janssen Research & Development LLC. A phase 2a multicenter randomized double-blind study evaluating the efficacy and safety of subcutaneously administered guselkumab and golimumab combination therapy in participants with active psoriatic arthritis [internet]. Report no.: NCT05071664. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05071664"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103865"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1283251"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.112"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2025-5-1"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1403a166"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11097"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221422"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205322"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254"},{"key":"e_1_3_6_128_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041275"},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0377-2"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020719"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab740"},{"key":"e_1_3_6_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.10.002"},{"key":"e_1_3_6_134_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003809"},{"key":"e_1_3_6_135_1","doi-asserted-by":"publisher","DOI":"10.1177\/24755303251394308"},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215210"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209853"},{"key":"e_1_3_6_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.12.008"},{"key":"e_1_3_6_139_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3593-x"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2601050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T10:37:18Z","timestamp":1766745438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2601050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":137,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,11,22]]}},"alternative-id":["10.1080\/14656566.2025.2601050"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2601050","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}